Skip to main content
. 2022 Nov 3;12(11):1493. doi: 10.3390/brainsci12111493

Figure 1.

Figure 1

(A) PNU120596 (PNU) reduced LPS-elevated HAAO expression in the hippocampus and prefrontal cortex. LPS (1 mg/kg) significantly increased HAAO expression in the hippocampus (p < 0.01) or prefrontal cortex (p < 0.05) than controls. PNU (4 mg/kg) significantly (p < 0.05) reduced HAAO expression in the hippocampus or prefrontal cortex than the LPS-treated group. (B) Effects of PNU on the HAAO immunoreactivity in the DG and CA1 regions of the mouse hippocampus and prefrontal cortex. LPS (1 mg/kg) significantly elevated HAAO expression in DG (p < 0.01), CA1 (p < 0.05) or prefrontal cortex (p < 0.01) than control group. PNU (4 mg/kg) significantly (p < 0.05) attenuated HAAO expression in the DG, CA1 or prefrontal cortex than the LPS-treated group. (C) Representative images of immunofluorescence in DG, CA1, and prefrontal cortex. Magnification 20×, scale bar = 50 μm. # p < 0.05 or ## p < 0.01, LPS (1 mg/kg) vs. control; * p < 0.05, PNU (4 mg/kg) + LPS vs. LPS alone; + p < 0.05, MLA (3 mg/kg) + PNU (4 mg/kg) + LPS vs. PNU (4 mg/kg) + LPS. Data are expressed as mean ± SEM (4–7 mice/group).